Share on StockTwits

Inovio Pharmaceuticals (NYSE:INO) saw a significant growth in short interest in May. As of May 30th, there was short interest totalling 31,788,308 shares, a growth of 3.6% from the May 15th total of 30,684,543 shares, Analyst Ratings News reports. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 4,240,257 shares, the short-interest ratio is presently 7.5 days.

A number of research firms have recently commented on INO. Analysts at Aegis reiterated a “hold” rating on shares of Inovio Pharmaceuticals in a research note on Monday. Finally, analysts at Stifel Nicolaus initiated coverage on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 7th. They set a “buy” rating and a $16.00 price target on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Inovio Pharmaceuticals has a consensus rating of “Buy” and an average target price of $18.96.

Inovio Pharmaceuticals (NYSE:INO) traded down 13.36% on Tuesday, hitting $9.34. The stock had a trading volume of 11,407,818 shares. Inovio Pharmaceuticals has a 52-week low of $2.44 and a 52-week high of $15.80. The stock’s 50-day moving average is $9.21 and its 200-day moving average is $10.65. The company’s market cap is $561.9 million.

Inovio Pharmaceuticals (NYSE:INO) last announced its earnings results on Monday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.04) by $0.01. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.41 million. On average, analysts predict that Inovio Pharmaceuticals will post $-0.69 earnings per share for the current fiscal year.

Inovio Pharmaceuticals, Inc is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.